Palliative therapy in cholangio- and gallbladder carcinoma;Palliative therapie von gallengangs- und gallenblasenkarzinomen

Zeitschrift fur Gastroenterologie

Volumn 44, Issue 7, 2006, Pages 587-598

  Klebl, Frank ^a   Endlicher, E ^a   Kullmann, F ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Cholangiocarcinoma; Cholangiocellular carcinoma; Gallbladder carcinoma; Klatskin's tumour

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; EXATECAN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRIDIUM 192; IRINOTECAN; METHOTREXATE; MITOMYCIN C; PACLITAXEL; RECOMBINANT ALPHA2B INTERFERON; ROFECOXIB; STREPTOZOCIN; TEGAFUR; URACIL;

BILE DUCT CARCINOMA; BILIARY TRACT DRAINAGE; BLOOD TOXICITY; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; GALLBLADDER CARCINOMA; GASTROENTEROSTOMY; HUMAN; PHOTODYNAMIC THERAPY; PROGNOSIS; REVIEW;

ANIMALS; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; GALLBLADDER NEOPLASMS; HUMANS; PALLIATIVE CARE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 33746674467     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-926869     Document Type: Review

References (138)

1. Khan SA, Thomas HC, Davidson BR et al. Cholangiocarcinoma. Lancet 2005; 366: 1303-1314
2. Misra S, Chaturvedi A, Misra NC et al. Carcinoma of the gallbladder. Lancet Oncol 2003; 4: 167-176
3. Rea DJ, Heimbach JK, Rosen CB et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242: 451-458
4. Herd M, Cosimi AB. Liver transplantation for malignancy. Oncologist 2005; 10: 269-281
5. Shaib Y, El-Serag HB. The epidemiology of Cholangiocarcinoma. Semin Liver Dis 2004; 24: 115-125
6. Farley DR, Weaver AL, Nagorney DM. "Natural history" of unresected Cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc 1995; 70: 425-429
7. Chang WH, Kortan P, Haber GB. Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc 1998; 47: 354-362
8. Berr F, Wiedmann M, Tannapfel A et al. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology 2000; 31: 291-298
9. Wiedmann M, Schoppmeyer K, Witzigmann H et al. Aktuelle Diagnostik und Therapie von Gallengangs- und Gallenblasenkarzinomen. Z Gastroenterol 2005;43:305-315
10. Khan SA, Davidson BR, Goldin R et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002; 51 (Suppl VI): vi1-vi9
11. Jakobs R, Weickert U, Hartmann D et al. Interventionelle Endoskopie bei benignen und malignen Gallengangsstenosen. Z Gastroenterol 2005;43:295-303
12. Kopf A, Bätjer N. Schmerztherapie in der gastroenterologischen Onkologie. Z Gastroenterol 2005; 43: 1061-1069
13. Abraham NS, Barkun JS, Barkun AN. Palliation of malignant biliary obstruction: a prospective trial examining impact on quality of life. Gastrointest Endosc 2002; 56: 835-841
14. Prat F, Chapat O, Ducot B et al. Predictive factors for survival of patients with inoperable malignant distal biliary strictures: a practical management guideline. Gut 1998; 42: 354-362
15. Deviere J, Baize M, de Toeuf J et al. Long-term follow-up of patients with hilar malignant stricture treated by endoscopic internal biliary drainage. Gastrointest Endosc 1988; 34: 95-101
16. De Palma GD, Galloro G, Siciliano S et al. Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointest Endosc 2001; 53: 547-553
17. Telford JJ, Carr-Locke DL, Baron TH et al. Palliation of patients with malignant gastric outlet obstruction with the enteral Wallstent: outcomes from a multicenter study. Gastrointest Endosc 2004; 60: 916-920
18. Schiefke I, Zabel-Langhennig A, Wiedmann M et al. Self-expandable metallic stents for malignant duodenal obstruction caused by biliary tract cancer. Gastrointest Endosc 2003; 58: 213-219
19. Bessoud B, de Baere T, Denys A et al. Malignant gastroduodenal obstruction: palliation with self-expanding metallic stents. J Vasc Interv Radiol 2005; 16: 247-253
20. Johnsson E, Thune A, Liedman B. Palliation of malignant gastroduodenal obstruction with open surgical bypass or endoscopic stenting: clinical outcome and health economic evaluation. World J Surg 2004; 28: 812-817
21. Nuzzo G, Clemente G, Cadeddu F et al. Palliation of unresectable periampullary neoplasms, "surgical" versus "non-surgical" approach. Hepatogastroenterology 2004; 51: 1282-1285
22. McCaughan JS, Mertens BF, Cho CH et al. Photodynamic therapy of non-resectable cholangiocarcinoma. Arch Surg 1991; 126: 111-113
23. Ortner MAEJ, Liebetruth J, Schreiber S et al. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology 1998; 114: 536-542
24. Harewood GC, Baron TH, Rumalla A et al. Pilot study to assess patient outcomes following endoscopic application of photodynamic therapy for advanced cholangiocarcinoma. J Gastroenterol Hepatol 2005; 20: 415-420
25. Dumoulin FL, Gerhardt T, Fuchs S et al. Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. Gastrointest Endosc 2003; 57: 860-867
26. Shim CS, Cheon YK, Cha SW et al. Prospective study of the effectiveness of percutaneous transhepatic photodynamic therapy for advanced bile duct cancer and the role of intraductal ultrasonography in response assessment. Endoscopy 2005; 37: 425-433
27. Wiedmann M, Berr F, Schiefke I et al. Photodynamic therapy in patients 0with non-resectable hilar cholangiocarcinoma: 5-year follow-up of a prospective phase II study. Gastrointest Endosc 2004; 60: 68-75
28. Ortner MAEJ, Caca K, Berr F et al. Successful photodynamic therapy for non-resectable cholangiocarcinoma: a randomised prospective study. Gastroenterology 2003; 125: 1355-1363
29. Gores GJ. A spotlight on cholangiocarcinoma. Gastroenterology 2003; 125: 1536-1538
30. Wiedmann M, Caca K, Berr F et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma. A Phase II study. Cancer 2003; 97: 2783-2790
31. Zoepf T, Jakobs R, Rosenbaum A et al. Photodynamic therapy with 5-aminolaevulinic acid is not effective in bile duct cancer. Gastrointest Endosc 2001; 54: 763-766
32. Zoepf T, Jakobs R, Arnold JC et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005; 100: 2426-2430
33. Nanashima A, Yamaguchi H, Shibasaki S et al. Adjuvant photodynamic therapy for bile duct carcinoma after surgery: a preliminary study. J Gastroenterol 2004; 39: 1095-1101
34. Ohnishi H, Asada M, Shichijo Y et al. External radiotherapy for biliary decompression of hilar cholangiocarcinoma. Hepatogastroenterology 1995; 42: 265-268
35. Kocak Z, Ozkan H, Adli M et al. Intraluminal brachytherapy with metallic stenting in the palliative treatment of malignant obstruction of the bile duct. Radiat Med 2005; 23: 200-207
36. Montemaggi P, Costamagna G, Dobelbower RR et al. Intraluminal brachytherapy in the treatment of pancreas and bile duct carcinoma. Int J Radiat Oncol Biol Phys 1995; 32: 437-443
37. Mayer R, Stranzl H, Prettenhofer U et al. Palliative treatment of unresectable bile duct tumours. Acta Med Austriaca 2003; 30: 10-12
38. Nakayama H, Tsuji K, Matsui R et al. External radiotherapy for decompression of cholangiocellular carcinoma with obstructive jaundice: report of a case. Radiat Med 2001; 19: 297-301
39. Shinchi H, Takao S, Nishida H et al. Length and quality of survival following external beam radiotherapy combined with expandable metallic stent for unresectable hilar cholangiocarcinoma. J Surg Oncol 2000; 75: 89-94
40. Milella M, Salvetti M, Cerrotta A et al. Interventional radiology and radiotherapy for inoperable cholangiocarcinoma of the extrahepatic bile ducts. Tumori 1998; 84: 467-471
41. Lu JJ, Bains YS, Abdel-Wahab M et al. High-dose-rate remote afterloading intracavitary brachytherapy for the treatment of extrahepatic biliary duct carcinoma. Cancer J 2002; 8: 74-78
42. Tsujino K, Landry JC, Smith RG et al. Definitive radiation therapy for extrahepatic bile duct carcinoma. Radiology 1995; 196: 275-280
43. Takamura A, Saito H, Kamada T et al. Intraluminal low-dose-rate 1921r brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol 2003; 57: 1357-1365
44. Shin HS, Seong J, Kim WC et al. Combination of external beam irradiation and high-dose-rate intraluminal brachytherapy for inoperable carcinoma of the extrahepatic bile ducts. Int J Radiat Oncol Biol Phys 2003; 57: 105-112
45. Gonzalez Gonzalez D, Gouma DJ, Rauws EA et al. Role of radiotherapy, in particular intraluminal brachytherapy, in the treatment of proximal bile duct carcinoma. Ann Oncol 1999; 10 (Suppl 4): S215-S220
46. Fritz P, Brambs HJ, Schraube P et al. Combined external beam radiotherapy and intraluminal high dose rate brachytherapy on bile duct carcinomas. Int J Radiat Oncol Biol Phys 1994; 29; 855-861
47. Kamada T, Saitou H, Takamura A et al. The role of radiotherapy in the management of extrahepatic bile duct cancer: an analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys 1996; 34: 767-774
48. Lameris JS, Stoker J, Nijs HG et al. Malignant biliary obstruction: percutaneous use of self-expandable stents. Radiology 1991; 179: 703-707
49. Shin HS, Seong J, Kim WC et al. Combination of external beam irradiation and high-dose-rate intraluminal brachytherapy for inoperable carcinoma of the extrahepatic bile ducts. Int J Radiat Oncol Biol Phys 2003; 57: 105-112
50. Bruha R, Petrtyl J, Kubecova M et al. Intraluminal brachytherapy and selfexpandable stents in nonresectable biliary malignancies - the question of long-term palliation. Hepatogastroenterology 2001; 48: 631-637
51. Kuvshinoff BW, Armstrong JG, Fong Y et al. Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy. Br J Surg 1995; 82: 1522-1525
52. Eschelman DJ, Shapiro MJ, Bonn J et al. Malignant biliary duct obstruction: long-term experience with Gianturco stents and combined modality radiation therapy. Radiology 1996; 200: 717-724
53. Ishii H, Furuse J, Nagase M et al. Relief of jaundice by external beam radiotherapy and intraluminal brachytherapy in patients with extrahepatic cholangiocarcinoma: results without stenting. Hepatogastroenterology 2004; 51: 954-957
54. Bowling TE, Galbraith SM, Hatfield AR et al. A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Gut 1996; 39: 852-855
55. Launois B, Reding R, Lebeau G et al. Surgery for hilar cholangiocarcinoma: French experience in a collective survey of 552 extrahepatic bile duct cancers. J Hepatobiliary Pancreat Surg 2000; 7: 128-134
56. Foo ML, Gunderson LL, Bender CE et al. External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma. Int J Rad Oncol Biol Phys 1997; 39: 929-935
57. Morganti AG, Trodella L, Valentini V et al. Combined modality treatment in unresectable extrahepatic biliary carcinoma. Int J Radiat Oncol Biol Phys 2000; 46: 913-919
58. Deodato F, Clemente G, Mattiucci GC et al. Chemoradiation and brachytherapy in biliary tract carcinoma: long-term results. Int J Radiat Oncol Biol Phys 2006; 64: 483-48 8
59. Matsumoto S, Kiyosue H, Komatsu E et al. Radiotherapy combined with transarterial infusion chemotherapy and concurrent infusion of a vasoconstrictor agent for nonresectable advanced hepatic hilar duct carcinoma. Cancer 2004; 100: 2422-2429
60. Schleicher UM, Staatz G, Alzen G et al. Combined external beam and intraluminal radiotherapy for irresectable Klatskin tumors. Strahlenther Onkol 2002; 178: 682-687
61. Gebbia V, Majello E, Testa A et al. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-flourouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Cancer 1996; 78: 1300-1307
62. Gelibter A, Malaguti P, Di Cosimo S et al. Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. Cancer 2005; 104: 1237-1245
63. Murad AM, Guimarães RC, Aragão BC et al. Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. Am J Clin Oncol 2003; 26: 151-154
64. Tsavaris N, Kosmas C, Couverts P et al. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 2004; 22: 193-198
65. Park JS, Oh SY, Kim SH et al. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol 2005; 35: 68-73
66. Knox JJ, Hedley D, Oza A et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005; 23: 2332-2338
67. Glimelius B, Hoffman K, Sjoden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600
68. Taïeb J, Mitry E, Boige V et al. Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol 2002; 13: 1192-1196
69. Knox JJ, Hedley D, Oza A et al. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers; a review of the Princess Margaret Hospital experience. Ann Oncol 2004; 15: 770-774
70. Kubicka S, Rudolph KL, Tietze MK et al. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 2001; 48: 783-789
71. Ducreux M, Van Cutsem E, Van Laethem JL et al. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40 955 EORTC trial. Eur J Cancer 2005; 41: 398-403
72. Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 1984; 54: 965-969
73. Choi CW, Choi IK, Seo JH et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 2000; 23: 425-428
74. Chen JS, Jan YY, Lin YC et al. Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas. Anticancer Drugs 1998; 9: 393-397
75. Raderer M, Hejna MHL, Valencak JB et al. Two consecutive phase II studies of 5-flourouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncol 1999; 56: 177-180
76. Von Delius S, Lersch C, Schulte-Frohlinde E et al. Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gall-bladder and biliary tract carcinoma. BMC Cancer 2005; 5: 61
77. Eng C, Ramathan RK, Wong MK et al. A phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol 2004; 27: 565-569
78. Penz M, Kornek GV, Raderer M et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001; 12: 183-186
79. Gallardo JO, Rubio B, Fodor M et al. A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 2001; 12: 1403-1406
80. Gebbia V, Giuliani F, Maiello E et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 2001; 19: 4089-4091
81. Mezger J, Sauerbruch T, Ko Yet al. Phase II study with gemcitabine in gallbladder and biliary tract carcinomas. Onkologie 1998; 21: 232-234
82. Valencak J, Kornek GV, Raderer M et al. Gemcitabine for the treatment of advanced biliary tract carcinomas: evaluation of two different dose regimens. Onkologie 1999; 22: 498-501
83. Okada S, Ishii H, Nose H et al. A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology 1994; 51: 515-517
84. Taal BG, Audisio RA, Bleiberg H et al. Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study. Ann Oncol 1993; 4: 607-609
85. Von Eyben F, Hellekant C, Mattsson W et al. Mitomycin C in advanced gallbladder carcinoma. Acta Radiol Oncol 1980; 19: 81-84
86. Jones DV, Lozano R, Hoque A et al. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 1996; 14: 2306-2310
87. Sanz-Altamira PM, O'Reilly E, Stuart KE et al. A phase II trial of irinotecan (CPT-II) for unresectable biliary tree carcinoma. Ann Oncol 2001; 12: 501-504
88. Alberts SR, Fishkin PA, Burgart LJ et al. CPT-II for bile-duct and gall-bladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study. Int J Gastrointest Cancer 2002; 32: 107-114
89. Abou-Alfa GK, Rowinsky EK, Patt YZ et al. A phase II study of intravenous exatecan administered daily for 5 days, every 4 weeks to patients with biliary tract cancers. Am J Clin Oncol 2005; 28: 334-339
90. Papakostas P, Kouroussis C, Androulakis N et al. First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study. Eur J Cancer 2001; 37: 1833-1838
91. Pazdur R, Royce ME, Rodriguez GI et al. Phase II trial of docetaxel for cholangiocarcinoma. Am J Clin Oncol 1999; 22: 78-81
92. Chen JS, Yang TS, Lin YC et al. A phase II trial of tegafur-uracil plus leucovorin (LV) in the treatment of advanced biliary tract carcinomas. Jpn J Clin Oncol 2003; 33: 353-356
93. Mani S, Sciortino D, Samules B et al. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Invest New Drugs 1999; 17: 97-101
94. Ikeda M, Okusaka T, Ueno H et al. A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma. Jpn J Clin Oncol 2005; 35: 439-443
95. Patt YZ, Hassan MM, Aguayo A et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004; 101: 578-586
96. Ueno H, Okusaka T, Ikeda M et al. Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 2004; 91: 1769-1774
97. Takada T, Kato H, Matsushiro T et al. Comparison of 5-fluorouracil, doxorubicin, and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 1994; 51: 396-400
98. Sanz-Altamira PM, Ferrante K, Jenkins RL et al. A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 1998; 82: 2321-2325
99. Chen JS, Lin YC, Jan YY et al. Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. Anti-Cancer Drugs 2001; 12: 339-343
100. Ducreux M, Rougier P, Fandi A et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 1998; 9: 653-656
101. Nehls O, Klump B, Arkenau HT et al. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer 2002; 87: 702-704
102. Boxberger F, Jüngert B, Brueckl V et al. Palliative chemotherapy with gemcitabine and weekly high-dose 5-flourouracil as 24-h infusion in metastatic biliary tract and gall bladder carcinoma. Anti-Cancer Drugs 2003; 14: 87-90
103. Hsu C, Shen YC, Yang CH et al. Weekly gemcitabine plus 24-h infusion of high-dose 5-flourouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. Br J Cancer 2004; 90: 1715-1719
104. Alberts SR, Al-Khatib H, Mahoney MR et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma. Cancer 2005; 103: 111-118
105. André T, Tournigand C, Rosmorduc O et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004; 15: 1339-1343
106. Kühn R, Hribaschek A, Eichelmann K et al. Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas. Invest New Drugs 2002; 20: 351-356
107. Thongprasert S, Napapan S, Charoentum C et al. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 2005; 16: 279-281
108. Kornek GV, Schuell B, Laengle F et al. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol 2004; 15: 478-483
109. Bhargava P, Jani CR, Savarese DM et al. Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report. Oncology (Williston Park) 2003; 17 (Suppl 8): 23-26
110. Cho JY, Paik YH, Chang YS et al. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer 2005; 104: 2753-2758
111. Malik IA, Aziz Z, Zaidi SH et al. Gemcitabine and cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder. Am J Clin Oncol 2003; 26: 174-177
112. Doval DC, Sektion JS, Gupta SK et al. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 2004; 90: 1516-1520
113. Kim TW, Chang HM, Kang HJ et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 2003; 14: 1115-1120
114. Patt YZ, Hassan MM, Lozano RD et al. Phase II trial of cisplatin, interferon a-2b, doxorubicin, and 5-flourouracil for biliary tract cancer. Clin Cancer Res 2001; 7: 3375-3380
115. Patt YZ, Jones DV, Hoque A et al. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 1996; 14: 2311-2315
116. Kajanti M, Pyrhonen S. Epirubicin-sequential methotrexate-5-fluorouracil- leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study. Am J Clin Oncol 1994; 17: 223-226
117. Ellis PA, Norman A, Hill A et al. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer 1995; 31A: 1594-1598
118. Lee MA, Woo IS, Kang JH et al. Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma. J Cancer Res Clin Oncol 2004; 130; 346-350
119. Park SH, Park YH, Lee JN et al. Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Cancer 2006; 106: 361-365
120. Park KH, Choi IK, Kim SJ et al. The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma. Cancer 2005; 103: 2338-2343
121. Harvey JH, Smith FP, Schein PS. 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 1984; 2: 1245-1248
122. Cho JY, Nam JS, Park MS et al. A phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma. Yonsei Med J 2005; 46: 526-531
123. Wu T. Cyclooxygenase-2 and prostaglandin signalling in cholangiocarcinoma. Biochim Biophys Acta 2005; 1755: 135-150
124. Reichle A, Klebl F, Bross K et al. Pioglitazone and rofecoxib combined with angiostatically scheduled capecitabine in far-advanced hepatobiliary carcinoma. Proceedings of the 3rd International Conference on Tumor Microenvironment. Prague/Czech Republic: October 12-16, 2004: 87-97
125. Sali A, McQuillan T, Read A et al. Rifampicin as cytotoxic agent for cholangiocarcinoma: preliminary report of seven cases. J Cancer Res Clin Oncol 1991; 117: 503-504
126. Makela JT, Kairaluoma MI. Superselective intra-arterial chemotherapy with mitomycin for gallbladder cancer. Br J Surg 1993; 80: 912-915
127. Tanaka N, Yamakado K, Nakatsuka A et al. Arterial chemoinfusion therapy through an implanted port system for patients with unresectable intrahepatic cholangiocarcinoma - initial experience. Eur J Radiol 2002; 41: 42-48
128. Cantore M, Mambrini A, Fiorentini G et al. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. Cancer 2005; 103: 1402-1407
129. Melichar B, German J, Dvorak J et al. Regional chemotherapy in biliary tract cancers - a single institution experience. Hepatogastroenterology 2002; 49: 900-906
130. Smith GW, Bukowski RM, Hewlett JS et al. Hepatic artery infusion of 5-fluorouracil and mitomycin C in cholangiocarcinoma and gallbladder carcinoma. Cancer 1984; 54: 1513-1516
131. Mezawa S, Homma H, Sato T et al. A study of carboplatin-coated tube for the unresectable cholangiocarcinoma. Hepatology 2000; 32: 916-923
132. Burger I, Hong K, Schulick R et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 2005; 16: 353-361
133. Berber E, Ari E, Herceg N et al. Laparoscopic radiofrequency thermal ablation for unusual hepatic tumors: operative indications and outcomes. Surg Endosc 2005; 19: 1613-1617
134. Kirchhoff T, Zender L, Merkesdal S et al. Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver. World J Gastroenterol 2005; 11: 1091-1095
135. Gaffke G, Gebauer B, Knollmann FD et al. Use of semiflexible applicators for radiofrequency ablation of liver tumors. Cardiovasc Intervent Radiol 2006; 29: 270-275
136. Shiozawa K, Ishii K, Mori T et al. Heterochronous development of intrahepatic cholangiocellular carcinoma following hepatocellular carinoma in a hepatits B virus carrier. Intern Med 2001; 40: 624-630
137. Zuber-Jerger I, Blum HE. Chologener Abszess nach lokaler Thermoablation eines cholangiozellulären Karzinoms. Dtsch Med Wochenschr 2003; 128: 2300-2302
138. Sheen AJ, Poston GJ, Sherlock DJ. Cryotherapeutic ablation of liver tumours. Br J Surg 2002; 89: 1396-1401